In its latest SEC filing for Q3, Banyan Capital Management Inc. initiated a stake of 3,853 shares in Johnson & Johnson valued at approximately $714,000, representing 0.3% of the firm’s overall portfolio and ranking J&J as its 22nd largest holding. This follows sizable purchases by Norges Bank (a new $4.88 billion stake in Q2) and Laurel Wealth Advisors (an additional 7.37 million shares worth $1.13 billion after a 15,040.6% increase), underscoring renewed institutional conviction in J&J’s diversified healthcare franchise. Vanguard increased its position by 1.3% to 237.05 million shares, while Geode and Legal & General added 1.23 million and 1.10 million shares respectively, bringing total institutional ownership to 69.55%.

The European CHMP granted a positive opinion to AKEEGA (niraparib + abiraterone) for BRCA1/2-mutant metastatic hormone-sensitive prostate cancer, positioning J&J for an incremental oncology revenue stream. Concurrently, a U.S. federal judge dismissed a fraud claim tied to the company’s talc bankruptcy strategy, reducing near-term litigation overhang. However, commentary from legal analysts cautions that broader talc liabilities remain unresolved, tempering the risk-reduction narrative. These developments should be monitored closely for their impact on J&J’s pharma growth trajectory and liability provisions.

Following Q4 results showing $2.46 EPS on $24.56 billion in revenue (up 9.1% year-over-year) and guidance of 11.43–11.63 EPS for FY2026, multiple brokerages raised targets: Daiwa to $237, Scotiabank to $265 and Morgan Stanley upgraded to Outperform citing a stronger growth outlook. Citigroup lifted its target to $250. J&J’s payout ratio stands at 47.1% after declaring a $1.30 quarterly dividend ($5.20 annualized, 2.3% yield), while its balance sheet metrics remain robust (debt/equity 0.50, current ratio 1.07), supporting both shareholder distributions and continued R&D investment.